Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $135.00

Kymera Therapeutics (NASDAQ:KYMR) had its price target upped by equities researchers at Guggenheim from $125.00 to $135.00 in a research note issued to investors on Tuesday, Marketbeat reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price objective suggests a potential upside of 22.67% from the company’s current price.

A number of other equities research analysts also recently issued reports on KYMR. Truist Financial upped their price objective on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Loop Capital set a $97.00 target price on Kymera Therapeutics in a report on Monday, June 8th. BTIG Research reaffirmed a “buy” rating and set a $134.00 price target on shares of Kymera Therapeutics in a research report on Thursday, June 25th. B. Riley Financial boosted their price objective on Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Finally, Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Twenty analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $124.68.

Kymera Therapeutics Trading Down 0.5%

Shares of KYMR stock opened at $110.05 on Tuesday. The firm has a fifty day simple moving average of $96.85 and a two-hundred day simple moving average of $86.91. Kymera Therapeutics has a 12 month low of $36.65 and a 12 month high of $130.05. The firm has a market capitalization of $9.05 billion, a PE ratio of -30.83 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same period in the prior year, the business posted ($0.82) earnings per share. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. On average, equities analysts predict that Kymera Therapeutics will post -3.28 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Bruce N. Jacobs sold 77,109 shares of Kymera Therapeutics stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total value of $8,864,450.64. Following the completion of the transaction, the chief financial officer directly owned 244,883 shares in the company, valued at approximately $28,151,749.68. The trade was a 23.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Nello Mainolfi sold 50,000 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $119.00, for a total value of $5,950,000.00. Following the sale, the chief executive officer owned 666,568 shares in the company, valued at approximately $79,321,592. This represents a 6.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 3,637,813 shares of company stock valued at $390,253,404. 15.98% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Hedge funds have recently bought and sold shares of the company. Baker BROS. Advisors LP lifted its stake in Kymera Therapeutics by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after purchasing an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC grew its position in shares of Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after purchasing an additional 1,124,747 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after purchasing an additional 845,922 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Kymera Therapeutics by 20.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after purchasing an additional 1,061,957 shares during the period. Finally, State Street Corp increased its holdings in shares of Kymera Therapeutics by 9.4% in the fourth quarter. State Street Corp now owns 2,209,837 shares of the company’s stock worth $171,947,000 after purchasing an additional 190,383 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.